论文部分内容阅读
中国抗艾药市场将达90亿元规模以上,市场前景光明,但要真正获益的前提,是要有性价比更优的新产品今年8月,中国疾控中心邵一鸣教授团队自主研制的艾滋病疫苗研发进入了II期临床实验。而就在1个月前,在华盛顿举行的19届世界艾滋病大会上,首位被治愈者现身。人们,似乎看到了控制艾滋病疫情的曙光。然而,过去30年对抗艾滋病的道路上,失败挫折屡屡袭来。大部分艾滋病疫苗都只走到了临床Ⅱ期且止步于临床Ⅱ期。进入临床Ⅲ期的疫苗屈指可数,即便进入最终也无不以失败告终。历经30年的求索,人们甚至开始怀疑,我们真的能研发出有效的HIV疫苗吗?
Chinese anti-AIDS drug market will reach 9 billion yuan in scale, the market prospects bright, but to really benefit from the premise that there must be better cost-effective new products August of this year, China CDC Dr. Shao Yiming team independently developed AIDS vaccine R & D entered Phase II clinical trials. Just a month ago, the first person to be cured appeared at the 19 World AIDS Conference in Washington. People seem to have seen the dawn of the AIDS epidemic. However, on the road to fighting AIDS in the past 30 years, the setbacks and failures have repeatedly hit. Most AIDS vaccines have only reached clinical stage II and stopped at stage II. Into the clinical phase III of the vaccine a handful, even into the final all without fail. After 30 years of searching, people even began to wonder whether we could really develop an effective HIV vaccine.